Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course and outcome. Recent advances in the diagnosis and molecular characterization of CLL permit improved prediction of disease prognosis, which could result in better management. We review the biology and diagnosis of CLL and the role of analysis of immunoglobulin heavy-chain variable region mutation status, molecular cytogenetics (interphase fluorescence in situ hybridization), and the expression of CD38 and ZAP-70 in the evaluation and management of patients with CLL.
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. zent.clive@mayo.edu
Clive S
CS
Zent
Neil E
NE
Kay
D051997:ADP-ribosyl Cyclase 1 / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000737:chemistry; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000737:chemistry; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000628:therapy*; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D012306:Risk; D012307:Risk Factors; D016896:Treatment Outcome; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D007143:Immunoglobulin Heavy Chains; D051746:ZAP-70 Protein-Tyrosine Kinase; D051997:ADP-ribosyl Cyclase 1